Figure 3.

Changes in immunity parameters at baseline, 1, 3, 7, 14, and 21 days after the first plasma infusion comparing the control group (CG) with the plasma group (PG). (A) Evolution of anti-SARS-CoV-2 S IgG serum titer (AU/mL) in CG and PG patients, expressed as mean ± SEM at each time point. *** p < 0.001, ** p < 0.01, when compared by two-way ANOVA repeat measures followed by the post hoc Tukey test, the levels of anti-SARS-CoV-2 S IgG serum titer at 21 days with respect to the baseline in each group. (B) Comparison of the anti-SARS-CoV-2 IgG serum titer (AU/mL) at 21 days respect the baseline, expressed as mean ± SEM, in CG and PG. *** p < 0.001, ** p < 0.01, when compared by one-way ANOVA followed by the post hoc Tukey test, the levels of anti-SARS-CoV-2 S IgG serum titer at 21 days with respect to the baseline in each group. (C) Correlation between the levels of anti-SARS-CoV-2 S IgG titers in PG serum vs. donor plasma bag received at 24 h after the last infusion; the correlation was performed using the Pearson test r² = 0.5, p < 0.05. (D) Distribution of the levels of anti-SARS-CoV-2 S IgG titers (AU/mL) in each group 24 h after the last plasma infusion. The horizontal bars indicate medians and the dotted line interquartile ranges. Each circle represents one patient.